secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071477
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark Therapeutics Q1 net loss $9.3M; cash $151.3M; Phase 3 PWS data expected early 2026
--------------------------------------------------------------------------------

- Net loss was $9.3M in Q1 2025 vs $2.2M in Q1 2024, driven by higher R&D and G&A costs.
- R&D expenses rose to $7.8M (from $1.2M) due to ARD-101 development and personnel costs.
- Cash, equivalents and short-term investments totaled $151.3M; IPO net proceeds were $87.5M.
- Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome; top-line data readout expected early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025071477/0000950170-25-071477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025071477/ck0001774857-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer